Morepen Laboratories Ltd

Morepen Lab Q4 net profit falls 31% to ₹20.31 cr, income up 10% at ₹470 cr

However, the company's total income has increased by 10.1 per cent to Rs 470.46 crore, from last year's Q4 income of Rs 427.31 crore.

These 3 pharma stocks have surged over 50% in April; check full list here

A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.

Morepen to hire 1,000 medical representatives to boost formulations biz

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

Morepen Labs rises 4% after China approves anti-allergy API export

The company commands an over 80 per cent market share in the US generics market for Loratadine, according to its filing

Smallcap index soars 2%; Gabriel, Avanti, Sarda Energy hit multi-year highs

However, thus far in the calendar year 2025, the BSE Smallcap index has underperformed the market by falling 20%, as against 14% decline in BSE Midcap index and 4% drop in BSE Sensex.

Morepen Labs shares skyrocket 12% on rolling out 'Empamore'; details here

The uptick in the Morepen Labs share came after the company announced that it has rolled out 'Empamore.'

Morepen Labs stock soars 6% on strong Q1 show; medical device biz grows 20%

Shares of Morepen Laboratories soared 6.46 per cent at Rs 61.89 per share on the BSE in Monday's intraday trade

Morepen Q4: Net profit falls 55% to Rs 12 cr, total income up to Rs 371 cr

Drug firm Morepen Laboratories on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

Morepen Labs starts production of Russia's Sputnik V Covid-19 vaccine

Pharma major Morepen Laboratories has started the production of the test batch of the Russian Sputnik V coronavirus vaccine in Himachal Pradesh, the company has said

Morepen Laboratories rallies 17% in two days on fundraising plans

Morepen Laboratories board approved the issue of up to 5 crore equity shares to Liquid Holdings, an entity belonging to the promoter group of the company, at a price of Rs 38 per equity share

Morepen Labs to raise over Rs 433 cr via issuance of preferential shares

Morepen Laboratories said its board has approved raising over Rs 433 crore through issue of shares to Switzerland's private venture capital firm Corinth Investment Holdings and Liquid Holdings

Morepen labs gets USFDA nod for cholesterol, asthma bulk drug mfg units

Atorvastatin and Montelukast have shown great growth potential during last 5 years, with a CAGR of 25% and 17% respectively